National Academies Press: OpenBook
« Previous: Appendix B: Workshop Agenda
Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2010. The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12856.
×

C
Registered Workshop Attendees

Terry Adirim

Department of Homeland Security


Will Alameida

PanThera Biopharma


Jennifer Alton

Bavarian Nordic


Margaret Anderson

FasterCures


Lida Anestidou

The National Academies


Marietta Anthony

Critical Path Institute


Stacy Arnesen

National Library of Medicine/National Institutes of Health


Damon Arnold

Illinois Department of Health


Phyllis Arthur

Biotechnology Industry Organization, Inc.


Bruce Artim

Eli Lilly and Company


Guillermo Aviles-Mendoza

HHS/ASPR


Sheila Avruch

Government Accountability Office


Gerrit Bakker

ASTHO


Tali Bar-Shalom

Government Accountability Office


Cindy Bascetta

Government Accountability Office


Alison L. Bawden

Soligenix, Inc.


Ketty Belizaire

TB Alliance


Georges Benjamin

American Public Health Association

Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2010. The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12856.
×

Kavita Berger

AAAS Center for Science, Technology and Security Policy


Kathleen Berst

CBMS-JVAP


Gregory Bice

ASDHA/FHP&R/DoD


Gary Bignami

PanThera Biopharma, LLC


Peter Blain

Health Protection Agency, UK


James Blumenstock

Association of State and Territorial Officials


Douglas Boenning

HHS


Brent Bomer

XOMA


Luciana Borio

FDA


Katie Brewer

American Nurses Association


Robert N. Brey

Soligenix, Inc.


Kathryn Brinsfield

Department of Homeland Security


Steve Brozak

StormBio Inc.


Greg Burel

Centers for Disease Control and Prevention/OPHPR


Stephen V. Cantrill

National Biodefense Science Board


Roberta Carlin

American Association on Health and Disability


Gail Cassell

Eli Lilly and Company


Stacey Chambers

HHS/NIH/NINDS


D. W. Chen

Department of Defense


Kelly Childress

Foley Hoag, LLP


Kenneth Cole

ODATSD (CBD/CD)/DoD


Susan Coller-Monarez

DHS


Chris Colwell

Becton Dickinson


Doug Compton

PhRMA


Francesca Cook

PharmAthene


Mark Cooke

PharmAthene


Susan Cooper

Tennessee Department of Health


Brian Corrigan

Astellas Pharma US, Inc.

Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2010. The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12856.
×

Allan Coukell

The Pew Charitable Trusts


Brooke Courtney

Center for Biosecurity


Dack Dalrymple

Dalrymple & Associates, LLC


Christopher Davis

HHS


Anne De Groot

EpiVax


Walla Dempsey

HHS/NIH/NIAID


Gary Disbrow

HHS/BioMedical Advanced Research and Development Authority


Jacqueline Dombroski

AVI BioPharma, Inc.


Michael Doney

Centers for Disease Control and Prevention


Matthew Duchars


Lydia Duckworth

MITRE/HHS


Melissa Dupree

Fabiani & Company


Diana Elkis

PRTM


Peter Emanuel

OSTP, White House


David Evans

U.S. Army Medical Research & Materiel Command


Daniel Fagbuyi

Children’s National Medical Center


Ann Farese

University of Maryland


Anthony Fauci

NIAID


Stuart Feldman

Sanofi Pasteur


Philip Ferro

HHS/ASPR


Patrick Flavin

Advanced Life Sciences, Inc.


Erin Fowler

HHS


Thomas Frieden

Centers for Disease Control and Prevention


Chuck Fromer

Chemical Biological Defense Directorate


Thomas Fuerst

HHS/ASPR


Nick Fullenkamp

Emergent BioSolutions


Claudia Gaffey

FDA


Alexander Garza

Department of Homeland Security

Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2010. The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12856.
×

Bruce Gellin

HHS


Jeanne Geyer

FDA


Brent Gibson

Atlas Research, LLC


David Gilbert

Providence Health & Services


Brett Giroir

Texas A&M


Lewis Goldfrank

New York University School of Medicine


Mark Goldberger

Abbott Labs


Michael Goldblatt

Functional Genetics


Phillip Gomez

PRTM


Jesse Goodman

FDA


Frank Gottron

Congressional Research Service, U.S. Library of Congress


John Grabenstein

Merck & Co., Inc.


Dwayne Grant

HHS/OIG


Gigi Gronvall

Center for Biosecurity of UPMC


Robert Guidos

Infectious Diseases Society of America


Elin Gursky

ANSER


James Guyton

PRTM Management Consultants


Jami Haberl

Safeguard Iowa Partnership


Jeff Hackman

Intercell


Nate Hafer

NIH/OD


Marlene Haffner

Haffner Associates, LLC


Veronica Hall

Emergent BioSolutions


Michael Handrigan

HHS/ASPR


Julie Hantman

HHS/ASPR/BARDA


Maureen Hardwick

Alliance for Biosecurity


Chandresh Harjivan

PRTM


Richard Hatchett

White House, Executive Office of the President


Herbert Hecht

Emergent BioSolutions

Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2010. The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12856.
×

William Helming

PRTM Management Consultants


D. A. Henderson

Center for Biosecurity of UPMC


David G. Henry

National Governors Association


Jack Herrmann

National Association of County and City Health Officials


Penny Hitchcock

Tauri Group


Sally Hojvat

OIVD/CDRH/FDA


Mary Homer

HHS/ASPR


Omar Hottenstein

Office of the Assistant Secretary of Defense for Health Affairs


Robert House

DynPort Vaccine Company, LLC


Jay Hunter

University of Maryland School of Medicine


Jean Hu-Primmer

FDA/Office of Counterterrorism and Emerging Threats


Patrick Iversen

AVI Biopharma


Rick Jaffe

ANSER, Inc., in support of ODATSD (CBD/CD)


James James

American Medical Association


Paul Jarris

Association of State and Territorial Health Officials


Daniel Jernigan

Centers for Disease Control and Prevention


David Jett

NIH/NINDS


Kelly Johnson

Agency for Healthcare Research and Quality


Vicki Johnson

National Commission on Children and Disasters


Jerry Johnston

National Association of Emergency Medical Technicians


Til Jolly

U.S. Department of Homeland Security, Office of Health Affairs


Robert Kadlec

PRTM Management Consultants


Brian Kamoie

White House, Executive Office of the President


Lisa Kaplowitz

Alexandria Health Department


James Kenimer

Biologics Consulting Group

Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2010. The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12856.
×

John Kenten

Meso Scale Diagnostics


Thomas Keuer

ARCA biopharma, Inc.


Rima Khabbaz

Centers for Disease Control and Prevention


Lynne Kidder

Business Executives for National Security


Hye-Joo Kim

Centers for Disease Control and Prevention/Regulatory Affairs


Lisa Koonin

Centers for Disease Control and Prevention


George Korch

HHS


Akhila Kosaraju

SIGA


Nik Koterski

U.S. Army Medical Research & Material Command


Gerald Kovacs

HHS/BioMedical Advanced Research and Development Authority


Jon Krohmer

Department of Homeland Security


Michael Kurilla

National Institute of Allergy and Infectious Diseases


Laura Kwinn

HHS


Anne Laffoon

Government Accountability Office


Randy Larsen

Commission on the Prevention of Weapons of Mass Destruction Proliferation and Terrorism


Michael Latham

Centers for Disease Control and Prevention


Catherine Laughlin

DMID, NIAID


James Lawler

White House, Executive Office of the President


Matthew Lawlor

HHS/ASPR/BARDA


Theresa Lawrence

HHS


Eva Lee

Center for Operations Research in Medicine and HealthCare, School of Industrial and Systems Engineering,

Georgia Tech University


Janet Leigh

LSU Health Sciences Center


Brad Leissa

FDA/CDER/OCTEC

Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2010. The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12856.
×

Rachel Levinson

Office of the Vice President for Research and Economic Affairs,

Arizona State University


Deborah Levy

Division of Healthcare Quality Promotion, CDC


Thomas Lilburn

Bayer Healthcare, LLC


Carol Linden

HHS/BARDA


Alicia Livinski

National Library of Medicine, National Institutes of Health


Cynthia Love

National Library of Medicine, National Institutes of Health

Daniel Lucey

Georgetown University Medical Center


Charles Ludlam

Former Counsel, Senator Joseph Lieberman


Former Principal Lobbyist for The Biotechnology Industry Organization


Nicole Lurie

HHS/ASPR


Boris Lushniak

FDA


Jayne Lux

National Business Group on Health


Brian Lynch

BD Medical


Thomas MacVittie

University of Maryland, School of Medicine


Carmen Maher

FDA


Bert Maidment

NIH/NIAID


Michael Mair

HHS


Don Malinowski

HHS/ASPR/NBSB Staff


Monique Mansoura

HHS/ASPR/BARDA


Maria Marinissen

HHS/ASPR


Richard Martin

American Society for Radiation Oncology


Tyler Martin

Dynavax Technologies


James Matthews

Sanofi Pasteur


Maritza McIntyre

Bavarian Nordic


Teri Melese

UCSF School of Medicine


Raina Merchant

HHS/ASPR

Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2010. The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12856.
×

Toby Merlin

Centers for Disease Control and Prevention


Jeremy Middleton

Elusys Therapeutics


Aubrey Miller

FDA


Georgianne Mitchell

City of Baltimore OEM


Thomas Monath

Kleiner Perkins Caufield & Byers


Melinda Moree

BIO Ventures for Global Health


Chanton Morel

London School of Economics


Carolina Morgan

Government Accountability Office


Erin Mullen

Rx Response


Rick Murray

American College of Emergency Physicians


Jomana Musmar

HHS/ASPR


Padma Natarajan

Infectious Diseases Society of America


Thomas Neal

MITRE


David Noll

Bavarian Nordic


Jeanne Novak

CBR International Corp.


Nancy Nurthen

Chemical Biological Defense Directorate


Michael Ochs

Infectious Diseases Society of America


Anthony Oliver

NHTSA, Office of Emergency Medical Services


Paul Owens

Lilly Research Laboratories


Christopher Ozeroff

ARCA biopharma, Inc.


George Painter

Chimerix, Inc.


Jennifer Pakiam

National Institutes of Health


Peter Palese

Mount Sinai School of Medicine, New York


Gerald Parker

HHS


John Parker

HHS


Tracy Parker

Department of Homeland Security

Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2010. The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12856.
×

Peter Patriarca

Biologics Consulting Group


Andrew Pavia

University of Utah School of Medicine


Raquel Peat

FDA/CDRH/OIVD/DMD


Mary Pendergast

ARCA biopharma, Inc.


Dana Perkins

HHS/ASPR


David Perryman

Zirus, Inc.


Del Persinger

PhRMA Foundation


Cheryl Peterson

American Nurses Association


Sally Phillips

Agency for Healthcare Research and Quality


William Pinard

American Association for the Advancement of Science


Douglas Pon

Pfizer, Inc.


Elizabeth Posillico

Elusys Therapeutics


Beena Puri

FDA/CDRH/OIVD/DMD


Resha Putzrath

Navy and Marine Corps Public Health Center


Beth Rada

XOMA


Narayani Ramakrishnan

National Institute of Allergy and Infectious Diseases


Jacqueline Rams

Southern Research Institute


Stephen Redd

Centers for Disease Control and Prevention


Christopher Revere

National Commission on Children and Disasters


John Rex

AstraZeneca


Andrew Rickles

HHS/ASPR


David Ridley

Duke University


Corinne M. Ringholz

Chemical Biological Defense Directorate


Rosemary Roberts

Center for Drug Evaluation and Research, FDA


MacKenzie Robertson

HHS/ASPR

Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2010. The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12856.
×

Robin Robinson

HHS


Michelle Rodrigues

SRI International


Paige Rogers

HHS/ASPR/BARDA


Eric Rose

SIGA Technologies, Inc


Philip Russell

Sabin Vaccine Institute


Jerald Sadoff

AERAS Global TB Vaccine Foundation


Elizabeth Sadove

FDA


Ronald Saldarini

Biological Initiatives


Emad Samad

StormBio


Tiffany Sampson

Department of Homeland Security


Leigh Sawyer

HHS


Patrick Scannon

XOMA


Julie Schafer

Biomedical Advanced Research and Development Authority


David Schmickel

FoxKiser


Roslyne Schulman

American Hospital Association


Talisha Searcy

HHS/OIG


Frederic Selck

Center for Biosecurity


Jonathan Shapiro

Department of Health and Human Services


Jerry Sheehan

National Library of Medicine National Institutes of Health


Marilee Shelton-Davenport

National Research Council/National Academy of Sciences


Angela Shen

National Vaccine Program Office, HHS


Thomas Shipley

Department of Homeland Security


Roxanne Shively

HHS/ASPR/BARDA


David Siegel

NIH, NICHD


Michael Skidmore

Department of Defense


Laura Smart

Chimerix


Brad Smith

Center for Biosecurity, UPMC

Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2010. The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12856.
×

Frank Sokolik

The Joint Commission


Daniel Sosin

Centers for Disease Control and Prevention


Raul Sotomayor

HHS/ASPR


Sharon Stanley

American Red Cross, National Headquarters


Craig Steinman

Abbott


Tim Stephens

National Sheriffs Association


Carolyn Stevens

HHS


Tom Stewart

AVI BioPharma


Deborah D. Stine

OSTP


Brook Stone

HHS/ASPR/NBSB


Raymond Strikas

National Vaccine Program Office, HHS


Victoria Sutton

Texas Tech University School of Law


Ernie Takafuji

National Institute of Allergy and Infectious Diseases


Carmen Tamayo

Foresight Links/FIP


Janet Tobias

Ikana Media


Eric S. Toner

Center for Biosecurity, University of Pittsburgh Medical Center


John Trizzino

Novavax, Inc.


Jessica Tucker

HHS


Craig Vanderwagen

HHS/ASPR (retired)


Rajeev Venkayya

Bill & Melinda Gates Foundation


Keith Vesely

Office of the Assistant Secretary of Defense for Health Affairs


Bruce Walker

Northrop Grumman Corporation


Cole Werble

The RPM Report


Gamunu Wijetunge

Department of Transportation


Ladd Wiley

Akin Gump Strauss Hauer and Feld


Andrew Willman

National Association of County and City Health Officials

Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2010. The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12856.
×

Theresa Wizemann

Wizemann Scientific Communications, LLC


April Wood

American Red Cross


Gillian Woollett

Engel & Novitt, LLP


Raymond Woosley

Critical Path Institute


Casey Wright

HHS/ASPR


David Wright

PharmAthene


Justin Wright

BD Medical


David Wurtman

NexBio, Inc.


Debra Yeskey

HHS/ASPR/BARDA


Kevin Yeskey

HHS


David Yeung

NIH/NINDS


Lauren Yeung

FDA


Wesley Yin

Boston University


Yon Yu

Centers for Disease Control and Prevention


Stephanie Zaza

Centers for Disease Control and Prevention

Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2010. The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12856.
×
Page 79
Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2010. The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12856.
×
Page 80
Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2010. The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12856.
×
Page 81
Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2010. The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12856.
×
Page 82
Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2010. The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12856.
×
Page 83
Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2010. The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12856.
×
Page 84
Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2010. The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12856.
×
Page 85
Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2010. The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12856.
×
Page 86
Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2010. The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12856.
×
Page 87
Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2010. The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12856.
×
Page 88
Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2010. The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12856.
×
Page 89
Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2010. The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12856.
×
Page 90
Next: Appendix D: Case Studies of HHS Chemical, Biological, Radiological, and Nuclear Medical Countermeasure Development Programs, Executive Summary »
The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary Get This Book
×
Buy Paperback | $59.00 Buy Ebook | $47.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

During public health emergencies such as pandemic influenza outbreaks or terrorist attacks, effective vaccines, drugs, diagnostics, and other medical countermeasures are essential to protecting national security and the public's well-being. The Public Health Emergency Medical Countermeasures Enterprise (PHEMCE)--a partnership among federal, state, and local governments; industry; and academia--is at the forefront of the effort to develop and manufacture these countermeasures. However, despite the PHEMCE's many successes, there are still serious challenges to overcome. Government-funded medical research is not always focused on countermeasures for the most serious potential threats, and it is difficult to engage pharmaceutical and biotechnology companies to develop and manufacture medical countermeasures that have a limited commercial market.

At the request of the Secretary of the U.S. Department of Health and Human Services and the Assistant Secretary for Preparedness and Response, the IOM held a workshop February 22-24, 2010, to address challenges facing the PHEMCE. Workshop participants discussed federal policies and procedures affecting the research, development, and approval of medical countermeasures and explored opportunities to improve the process and protect Americans' safety and health.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!